BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25944164)

  • 1. The role of osteopontin expression in melanoma progression.
    Kiss T; Ecsedi S; Vizkeleti L; Koroknai V; Emri G; Kovács N; Adany R; Balazs M
    Tumour Biol; 2015 Sep; 36(10):7841-7. PubMed ID: 25944164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of osteopontin expression in human gastric carcinoma.
    Higashiyama M; Ito T; Tanaka E; Shimada Y
    Ann Surg Oncol; 2007 Dec; 14(12):3419-27. PubMed ID: 17896150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor.
    Schultz J; Lorenz P; Ibrahim SM; Kundt G; Gross G; Kunz M
    Mol Carcinog; 2009 Jan; 48(1):14-23. PubMed ID: 18459127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpressed ostepontin-c as a potential biomarker for esophageal squamous cell carcinoma.
    Zhang MX; Xu YJ; Zhu MC; Yan F
    Asian Pac J Cancer Prev; 2013; 14(12):7315-9. PubMed ID: 24460294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of the upregulated osteopontin mRNA expression in human colorectal cancer.
    Likui W; Hong W; Shuwen Z
    J Gastrointest Surg; 2010 Jan; 14(1):74-81. PubMed ID: 19763701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
    Rouanne M; Adam J; Goubar A; Robin A; Ohana C; Louvet E; Cormier J; Mercier O; Dorfmüller P; Fattal S; de Montpreville VT; Lebret T; Dartevelle P; Fadel E; Besse B; Olaussen KA; Auclair C; Soria JC
    BMC Cancer; 2016 Jul; 16():483. PubMed ID: 27422280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteopontin promotes the invasive growth of melanoma cells by activating integrin αvβ3 and down-regulating tetraspanin CD9.
    Yin M; Soikkeli J; Jahkola T; Virolainen S; Saksela O; Hölttä E
    Am J Pathol; 2014 Mar; 184(3):842-58. PubMed ID: 24412090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of RUNX3 increases osteopontin expression and promotes cell migration in gastric cancer.
    Cheng HC; Liu YP; Shan YS; Huang CY; Lin FC; Lin LC; Lee L; Tsai CH; Hsiao M; Lu PJ
    Carcinogenesis; 2013 Nov; 34(11):2452-9. PubMed ID: 23774402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.
    Wu CY; Wu MS; Chiang EP; Wu CC; Chen YJ; Chen CJ; Chi NH; Chen GH; Lin JT
    Gut; 2007 Jun; 56(6):782-9. PubMed ID: 17148500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer.
    Rohde F; Rimkus C; Friederichs J; Rosenberg R; Marthen C; Doll D; Holzmann B; Siewert JR; Janssen KP
    Int J Cancer; 2007 Oct; 121(8):1717-23. PubMed ID: 17565744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Protein and mRNA expression of osteopontin in lung cancer and clinical significance thereof].
    Gui SY; Li HH; Zuo L; Zhou Q; Wu Q; Wang Y
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3219-23. PubMed ID: 18399118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing Osteopontin Expression Inhibits Proliferation, Invasion and Induce Altered Protein Expression in Melanoma Cells.
    Kiss T; Jámbor K; Koroknai V; Szász I; Bárdos H; Mokánszki A; Ádány R; Balázs M
    Pathol Oncol Res; 2021; 27():581395. PubMed ID: 34257527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group.
    Psyrri A; Kalogeras KT; Wirtz RM; Kouvatseas G; Karayannopoulou G; Goussia A; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Economopoulou P; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
    J Transl Med; 2017 Feb; 15(1):30. PubMed ID: 28193231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.
    Kadkol SS; Lin AY; Barak V; Kalickman I; Leach L; Valyi-Nagy K; Majumdar D; Setty S; Maniotis AJ; Folberg R; Pe'er J
    Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):802-6. PubMed ID: 16505010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and clinical significance of osteopontin in calcified breast tissue.
    Huan JL; Xing L; Qin XJ; Gao ZG; Pan XF; Zhao ZD
    Asian Pac J Cancer Prev; 2012; 13(10):5219-23. PubMed ID: 23244138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up.
    Cabiati M; Gaggini M; Cesare MM; Caselli C; De Simone P; Filipponi F; Basta G; Gastaldelli A; Del Ry S
    Cytokine; 2017 Nov; 99():59-65. PubMed ID: 28711012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
    Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
    Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.